Home » Stocks » AUPH

Aurinia Pharmaceuticals Inc. (AUPH)

Stock Price: $14.45 USD 0.50 (3.55%)
Updated Jun 24, 2021 2:11 PM EDT - Market open
Market Cap 1.77B
Revenue (ttm) 51.00M
Net Income (ttm) -136.53M
Shares Out 128.16M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE 434.78
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $14.45
Previous Close $13.95
Change ($) 0.50
Change (%) 3.55%
Day's Open 14.06
Day's Range 14.00 - 14.75
Day's Volume 2,445,355
52-Week Range 9.72 - 20.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VICTORIA, British Columbia--(BUSINESS WIRE)---- $AUPH--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., P...

1 week ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company ...

2 weeks ago - Business Wire

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented an analysis of its Phase 3 AURORA 1 study da...

2 weeks ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fi...

4 weeks ago - Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in lupus nephritis. Data will be presented at ...

1 month ago - Benzinga

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today that a supportive interim analysis of its AU...

1 month ago - Business Wire

Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt.

Other stocks mentioned: AGEN
1 month ago - The Motley Fool

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two ...

1 month ago - Business Wire

Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today, in recognition of World Lupus Day, affirmed its commi...

1 month ago - Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced that The Lancet published its Phase 3 AURORA 1 study evaluating Lupkynis (voclosporin) in adults with lupus nephritis (LN). The study results dem...

1 month ago - Benzinga

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that The Lancet, an international, peer-...

1 month ago - Business Wire

Aurinia (AUPH) delivered earnings and revenue surprises of -14.29% and -60.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Expectations for the biotech's first-quarter sales may have been too high.

1 month ago - The Motley Fool

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights

1 month ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thurs...

1 month ago - Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) was trending Tuesday afternoon possibly amid the stock making a new 52-week low. Below are the technical levels to watch on the chart.

2 months ago - Benzinga

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fi...

2 months ago - Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus nephritis (LN). Aurinia shared the data at the N...

2 months ago - Benzinga

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV an...

2 months ago - Business Wire

AUPH stock still has to prove its Lupus drug can sell and its price and the competition make that an unclear proposition. The post Aurinia Stock Has Great Potential, but It's Not a Buy Right Now appeare...

2 months ago - InvestorPlace

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-ef...

3 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in mult...

3 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended ...

3 months ago - Business Wire

Aurinia Pharmaceuticals (NASDAQ:AUPH) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.

4 months ago - Benzinga

Aurinia (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fi...

4 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial re...

4 months ago - Business Wire

In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications. I then consider more factors in the comparison to competitor drug Benlysta.

4 months ago - Seeking Alpha

Approval of a new lupus treatment has investors buzzing around this biotech stock.

4 months ago - The Motley Fool

The FDA approved the drugmaker's closely watched lupus nephritis therapy.

4 months ago - The Motley Fool

AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve the company'...

Other stocks mentioned: AZN, CNST, REGN
4 months ago - Benzinga

Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.

4 months ago - Zacks Investment Research

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administrati...

5 months ago - Business Wire

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming v...

5 months ago - Business Wire

Aurinia (AUPH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

AUPH stock has fallen on two recent developments. I analyze these and argue that the second, a new licensing agreement, is not negative, rather it's a positive for stockholders.

6 months ago - Seeking Alpha

Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks. Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug Voclosporin.

6 months ago - Seeking Alpha

Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs

Other stocks mentioned: UBX
6 months ago - GuruFocus

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and l...

6 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive ma...

6 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare ...

6 months ago - Business Wire

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Other stocks mentioned: INSM, CYTK, NEO, TPTX
6 months ago - Insider Monkey

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - Business Wire

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fires...

7 months ago - Business Wire

This biotech titan should be a top player on the merger and acquisition scene next year.

Other stocks mentioned: BIIB, HRTX, SAVA
7 months ago - The Motley Fool

Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

7 months ago - Zacks Investment Research

Aurinia (AUPH) delivered earnings and revenue surprises of -27.27% and -50.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 0.15% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 33.33% year over year to ($0.28),...

7 months ago - Benzinga

About AUPH

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Industry
Biotechnology
IPO Date
Jan 26, 1999
CEO
Peter Greenleaf
Employees
294
Stock Exchange
NASDAQ
Ticker Symbol
AUPH
Full Company Profile

Financial Performance

In 2020, AUPH's revenue was $50.12 million, an increase of 15,660.38% compared to the previous year's $318,000. Losses were -$102.68 million, 16.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is 11.50, which is a decrease of -20.39% from the latest price.

Price Target
$11.50
(-20.39% downside)
Analyst Consensus: Strong Buy